MX2018006005A - Formulaciones que comprenden sales de oxalato de teneligliptin y solvatos de este. - Google Patents

Formulaciones que comprenden sales de oxalato de teneligliptin y solvatos de este.

Info

Publication number
MX2018006005A
MX2018006005A MX2018006005A MX2018006005A MX2018006005A MX 2018006005 A MX2018006005 A MX 2018006005A MX 2018006005 A MX2018006005 A MX 2018006005A MX 2018006005 A MX2018006005 A MX 2018006005A MX 2018006005 A MX2018006005 A MX 2018006005A
Authority
MX
Mexico
Prior art keywords
teneligliptin
solvates
formulations
oxalate salts
pharmaceutically acceptable
Prior art date
Application number
MX2018006005A
Other languages
English (en)
Spanish (es)
Inventor
Rameshchandra Dhuppad Ulhas
Mahadev Kadam Suresh
Parsottam Kansagra Bipin
Bhaskar Bhirud Shekhar
Kantilal Kale Shrikrishna
Kumar Dwivedi Rajesh
Shivajirao Deshmukh Nitin
Prakashrao Sadaphal Krishna
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63039388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018006005(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of MX2018006005A publication Critical patent/MX2018006005A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2018006005A 2017-02-03 2018-02-02 Formulaciones que comprenden sales de oxalato de teneligliptin y solvatos de este. MX2018006005A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721004095 2017-02-03
PCT/IB2018/050662 WO2018142334A1 (en) 2017-02-03 2018-02-02 Formulations comprising oxalate salts of teneligliptin and solvates thereof

Publications (1)

Publication Number Publication Date
MX2018006005A true MX2018006005A (es) 2019-05-16

Family

ID=63039388

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018006005A MX2018006005A (es) 2017-02-03 2018-02-02 Formulaciones que comprenden sales de oxalato de teneligliptin y solvatos de este.
MX2018006006A MX2018006006A (es) 2017-02-03 2018-02-02 Sales de oxalato de teneligliptin y solvatos de este, intermediarios, proceso de preparacion y marcadores de estos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018006006A MX2018006006A (es) 2017-02-03 2018-02-02 Sales de oxalato de teneligliptin y solvatos de este, intermediarios, proceso de preparacion y marcadores de estos.

Country Status (10)

Country Link
JP (2) JP2019508385A (zh)
KR (2) KR20180100554A (zh)
CN (2) CN108884089A (zh)
AU (2) AU2018202623A1 (zh)
BR (2) BR112018010748A2 (zh)
EA (1) EA039402B1 (zh)
MX (2) MX2018006005A (zh)
RU (2) RU2018120216A (zh)
TW (2) TW201831473A (zh)
WO (2) WO2018142334A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020209350A1 (zh) * 2019-04-12 2020-10-15
CN110028496A (zh) * 2019-04-26 2019-07-19 梯尔希（南京）药物研发有限公司 一种特力利汀相关杂质的合成方法
WO2021053564A1 (en) * 2019-09-17 2021-03-25 Glenmark Pharmaceuticals Limited Pharmaceutical composition comprising remogliflozin or salt or ester thereof and teneligliptin or salt thereof
KR20210121421A (ko) 2020-03-30 2021-10-08 코오롱생명과학 주식회사 테네리글리프틴 2.5브롬화수소산염 무정형의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI319322B (en) * 2003-11-13 2010-01-11 Ono Pharmaceutical Co Frozen-dried preperation containing prostaglandin
AU2006215041B2 (en) * 2005-02-18 2012-05-31 Mitsubishi Tanabe Pharma Corporation Salt of proline derivative, solvate thereof, and production method thereof
JP2012517977A (ja) * 2009-02-13 2012-08-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬
KR102668834B1 (ko) * 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US9572806B2 (en) * 2009-12-18 2017-02-21 Mitsubishi Tanabe Pharma Corporation Elution-stabilized preparation
RU2654069C2 (ru) * 2012-08-31 2018-05-16 Гленмарк Фармасьютикалс Лимитед Способ получения тенелиглиптина
JP6088872B2 (ja) * 2013-03-22 2017-03-01 サラヤ株式会社 ラクトン型ソホロリピッドの分解が抑制されたソホロリピッド粉末
WO2015012365A1 (ja) * 2013-07-25 2015-01-29 株式会社 三和化学研究所 医薬製剤
WO2015019238A1 (en) * 2013-08-06 2015-02-12 Ranbaxy Laboratories Limited Process for the preparation of n-protected (5s)-5-(1,3-thiazolidin-3-ylcarbonyl)pyrrolidin-3-one
CN104650065A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 一种替格列汀化合物
WO2015132679A1 (en) * 2014-03-05 2015-09-11 Glenmark Pharmaceuticals Ltd Teneligliptin compositions
WO2015173779A1 (en) * 2014-05-16 2015-11-19 Micro Labs Limited Process for the preparation of teneligliptin and its novel intermediates
CN105294673B (zh) * 2014-06-18 2018-04-13 四川科伦药物研究院有限公司 一种氢溴酸替格列汀的合成方法
EP3201191A1 (en) * 2014-10-01 2017-08-09 Mylan Laboratories Ltd. Complex of amorphous empagliflozin and a cyclodextrin
JP6027710B1 (ja) * 2014-12-25 2016-11-16 田辺三菱製薬株式会社 糖尿病治療用固形製剤

Also Published As

Publication number Publication date
RU2742418C1 (ru) 2021-02-05
RU2018120216A (ru) 2021-05-07
EA039402B1 (ru) 2022-01-24
KR20180099635A (ko) 2018-09-05
AU2018202623A1 (en) 2018-08-23
JP2019512460A (ja) 2019-05-16
AU2018202960A1 (en) 2018-08-23
BR112018010748A2 (pt) 2018-12-04
BR112018010759A2 (pt) 2018-12-04
TW201834655A (zh) 2018-10-01
WO2018142327A1 (en) 2018-08-09
TW201831473A (zh) 2018-09-01
JP2019508385A (ja) 2019-03-28
CN108884089A (zh) 2018-11-23
CN108697707A (zh) 2018-10-23
MX2018006006A (es) 2019-05-16
EA201992376A1 (ru) 2020-03-23
WO2018142334A1 (en) 2018-08-09
KR20180100554A (ko) 2018-09-11

Similar Documents

Publication Publication Date Title
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MX2021009673A (es) Moduladores de ror-gamma.
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11202006782YA (en) Topical formulations comprising tofacitinib
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2018006005A (es) Formulaciones que comprenden sales de oxalato de teneligliptin y solvatos de este.
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
NZ737892A (en) Muscarinic m1 receptor positive allosteric modulators
PH12020550537A1 (en) Bicyclic sulfones and sulfoxides and methods of use thereof
IL279284A (en) Topical detomidine formulations
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
MA39450A1 (fr) Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine
PH12017502148A1 (en) Pharmaceutical compositions and use thereof
NZ712341A (en) A crystalline form of an anxiolytic compound
PH12020550185A1 (en) Semaglutide in medical therapy
WO2018119108A8 (en) Solid pharmaceutical formulations of asimadoline
PH12017501736A1 (en) Indole derivatives
MX2019005495A (es) Composicion para el cuidado bucal.
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof